H.R. 5485 — Second Chance at Life Act of 2025

This section requires abortion providers to obtain informed consent from women prior to performing chemical abortions (i.e., use or prescription of an abortion-inducing drug, such as the two-drug regimen of mifepristone followed by misoprostol, intended to cause the death of an unborn child), including disclosure of the possibility of reversing mifepristone's effects if the woman changes her mind, effective 30 days after enactment. Specifically, it mandates (1) informing the woman by telephone or in person at least 24 hours before the procedure, including that time is of the essence and directing her to an HHS website for reversal information; (2) providing written discharge instructions after dispensing mifepristone stating that it alone may not end the pregnancy and reversal may be possible before taking misoprostol; (3) posting signs with reversal information in patient areas of facilities performing chemical abortions, in at least three-quarters-inch boldfaced type; and (4) an exception for medical emergencies threatening the woman's life, certified in her medical file. It further directs the HHS Secretary, within 30 days of enactment, to publish multilingual printed materials on reversal possibilities and resources and to maintain a public website providing that information (with no user data collection, anti-tampering monitoring, and specified technical standards).

This section provides that nothing in this Act preempts state laws establishing, implementing, or continuing disclosure requirements regarding abortion or penalties for noncompliance that are more extensive than those required by the Act.